University Hospitals Seidman Cancer Center treats its first glioblastoma patient with genetically modified poliovirus

University Hospitals Seidman Cancer Center treated its first patient in a new clinical trial to validate the groundbreaking effects of the poliovirus on glioblastoma (GBM), a deadly Grade IV cancer of the brain.

UH is the only Midwest site participating in this clinical trial, which was initiated at Duke Cancer Institute in Durham, NC. The original study, which ran from 2012-2017, was published in New England Journal of Medicine in July 2018 as well as highlighted on “60 Minutes” in 2015 and again in 2018. The study found that survival rates were significantly higher in glioblastoma patients who received an intratumoral infusion of a modified viral chimera combining the polio and rhinoviruses (PVSRIPO immunotherapy) compared to patients receiving standard treatment at the same institution.

Read more

Guiding Lights: UC San Diego Launches Center for Fluorescence-Guided Surgery

UC San Diego launches new Center for Fluorescence-Guided Surgery. The center builds upon Roger Tsien’s legacy, delivering a new caliber of surgical precision to treat patients with tumors and disease of all types, identifying unhealthy tissues with a fluorescent glow.

Read more

A Rare Diagnosis Leads to a Successful Surgery and Recovery

Drew, a 65-year-old man from Connecticut, was diagnosed with a spinal dural arteriovenous fistula (SDAVF), which is a rare vascular malformation of the spinal cord that only affects 1 in every 200,000 people.

SDAVFs are underdiagnosed because symptoms can be vague and mirror many other types of medical problems. If left untreated, SDAVFs can result in permanent spinal cord injury.

Despite the uncommon diagnosis, a multidisciplinary care team from Nuvance Health, including primary care, neurology, radiology, and neurosurgery correctly and expeditiously identified and surgically treated Drew’s SDAVF.

Read more